ClinicalTrials.gg
CompletedNCT00154375Updated Apr 26, 2011Results posted

Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma

A Phase 3 interventional study of Imatinib mesylate and Hydroxyurea in Glioblastoma Multiforme and Astrocytoma, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2011-04-26.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing imatinib in Glioblastoma — none open to participants now, none under way, none of them phase 3. imatinib · Glioblastoma.

Enrollment
Largest of 10
240 · median 65
Started
2004
with 2 others
Phase 3
Only one
of the 10
Registered
3rd of 10
by date
Lead sponsor
1 of 10
Novartis Pharmaceuticals

Among the 10 studies testing imatinib in Glioblastoma, this one has the largest enrollment, is one of 3 that started in 2004, is the only one in phase 3, and was the 3rd registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

None of the 10 studies testing imatinib in Glioblastoma is open now. The open studies under Glioblastoma, anywhere →

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing imatinib in Glioblastoma as a file.
02

Study summary

This is a Phase III study comparing Imatinib mesylate and hydroxyurea combination therapy with hydroxyurea monotherapy in patients with temozolomide resistant progressive glioblastoma.

03

Conditions studied

  • Glioblastoma Multiforme
  • Astrocytoma

Keywords

  • Open label
  • Imatinib mesylate
  • hydroxyurea
  • temozolomide
  • resistant
  • protein tyrosine kinases
  • adenocarcinoma
  • glioblastoma multiforme
  • astrocytoma
  • brain tumor
  • brain cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to initiation of any study procedure.
  • Patients >= 18 years of age.
  • Histological confirmed diagnosis of glioblastoma multiforme / astrocytoma World Health Organization (WHO) grade IV by a reference pathologist
  • (ECOG) Performance Status of 0, 1 or 2.
  • Adequate hepatic, renal and bone marrow function as defined by the following: total \< 1.5 x (ULN), and AST \< 2.5 x ULN, creatinine \< 1.5 x ULN, > 1.5 x109/L, > 100 x109/L and > 10 g/dL.
  • Female patients of with a negative pregnancy test within 7 days of initiation of study drug dosing. women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of who agree to employ an effective barrier method of throughout the study, and for up to 3 months following discontinuation of study drug.
  • of >3 months.
  • MRI available every 6 weeks for disease management
  • No intercerebral inflammation
  • Irradiation therapy 54 to 62 gy finished or less according to national standard
  • Chemotherapy at least 1 temozolomide containing regimen finished, no established chemotherapy regiment available and progression under chemotherapy or in between 6 months following the last chemotherapy.
  • Leucocytes > 2.500/µl, to be controlled once a week
  • Thrombocytes > 80.000/µl, to be controlled once a week
  • Ensured compliance
  • Patients who had a second or third resection after disease progression cannot be included earlier than 2 weeks following the resection. MRI should be performed not later than 72 h post operation. If patients are to be included later than 4 weeks after the resection, a new baseline MRI must be performed.

Exclusion criteria

Exclusion Criteria:

  • Female patients who are pregnant or breast-feeding.
  • Patients who have been treated with any agent(s) within 28 days of the first day of administration of study drug.
  • Patients with uncontrolled medical disease such as diabetes mellitus, thyroid dysfunction, neuropsychiatric disorders, infection, angina or Grade 3 or 4 cardiac problems as defined by the Criteria.
  • Patients with other malignant disorders.
  • Patient with acute or known chronic liver disease (i.e., chronic active hepatitis, cirrhosis).
  • Patients who are known to be positive (no specific tests are required for confirmation of eligibility).
  • Expected incompliance according to treatment, treatment diary and examination schedule
  • Not confirmed histological diagnosis glioblastoma multiforme/astrocytoma WHO grade IV
  • Other drugs with potential cytostatic main or side effect
  • No or inadequate chemotherapy or irradiation therapy
  • Patients without hematological recovery after previous chemotherapy who have been treated with Chemotherapy within 28 days of the first day of administration of study drug.

Other protocol-specific inclusion /exclusion criteria may apply.

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
240 participants (actual)

Study arms

  • Experimental
    Imatinib mesylate + hydroxyurea (HU)

    Imatinib was supplied as 100 mg and 400 mg tablets. Patients in the combination arm were instructed to take a daily oral imatinib dose of 600 mg (600 mg at lunch time) and a daily oral hydroxyurea (HU) dose of 1000 mg (500 mg twice daily; in the morning and at bed time). Every 6 weeks after randomization based on assessment of therapeutic response, either patients continued with above mentioned dosing regimen or switched to receive a daily dose of 800 mg imatinib with 1000 mg HU. Patients were instructed to split the intake, taking 400 mg imatinib with 500 mg HU in the morning, then the same in the evening.

    Drug: Imatinib mesylate · Drug: Hydroxyurea

  • Active comparator
    Hydroxyurea alone

    1500 mg/day of HU given as 500 mg 3 times daily. Every 6 weeks after randomization and based on assessment of therapeutic response, the patients were either switched to combination arm or continued in monotherapy arm of hydroxyurea.

    Drug: Hydroxyurea

Interventions

  • Imatinib was supplied as 100 mg and 400 mg tablets packaged in polyethylene bottles.

    Also known as: Glivec®

  • Also known as: Litalir®

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Progression Free Survival (PFS) During the Study Duration

    PFS was defined as the time from the date of randomization to the date of the first documented progression according to the MacDonald criteria, or death due to any cause. MacDonald criteria are standard criteria in neurooncology. Tumor assessment was made according to the adapted MacDonald criteria based on the combined evaluation of 1) assessment of the MRI scan for measurable, evaluable, and new lesions (made by the independent external expert too), 2) overall assessment of neurological performance (made by the investigator), 3) concomitant steroid use (as reported by the investigator).

    Time frame: 6 months -1 year

Secondary outcomes

  1. Number of Participants With Death, Other Serious or Clinically Significant Adverse Events (AEs) or Related Discontinuations

    National Cancer Institute (NCI)/ National Institute of Health (NIH) provides a grading (severity) scale for each AE term. Grade 3 refers to severe AE and Grade 4 refers to life-threatening or disabling AE. According to FDA 21CFR 314.80, a serious adverse event (SAE) is described as any adverse event that leads to death, is life threatening ( NIH criteria Grade 4), causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above.

    Time frame: 6 months - 1 year

07

Results

Posted Feb 2, 2011

Participant flow

Participant flow — Overall Study
MilestoneImatinib Mesylate + Hydroxyurea (HU)Hydroxyurea Alone
Started120120
Discontinued study treatment111104
Not exposed to study treatment22
Completed714
Not completed113106
Withdrew: Unsatisfactory therapeutic effect2526
Withdrew: Adverse event1820
Withdrew: Withdrawal by subject1410
Withdrew: Death513
Withdrew: Study drug no longer required53
Withdrew: Lost to follow-up21
Withdrew: Abnormal laboratory value(s)02
Withdrew: Protocol violation01
Withdrew: Suspected progression of disease4430

Outcome measures

PrimaryPercentage of Participants With Progression Free Survival (PFS) During the Study Duration

PFS was defined as the time from the date of randomization to the date of the first documented progression according to the MacDonald criteria, or death due to any cause. MacDonald criteria are standard criteria in neurooncology. Tumor assessment was made according to the adapted MacDonald criteria based on the combined evaluation of 1) assessment of the MRI scan for measurable, evaluable, and new lesions (made by the independent external expert too), 2) overall assessment of neurological performance (made by the investigator), 3) concomitant steroid use (as reported by the investigator).

Time frame:
6 months -1 year
Reported as:
Number · Percentage of Participants
Percentage of Participants With Progression Free Survival (PFS) During the Study Duration
Percentage of ParticipantsImatinib Mesylate + Hydroxyurea (HU)Hydroxyurea Alone
6 months5.3 (1.0 to 9.7)6.6 (2.1 to 11.1)
12 months2.1 (0.0 to 5.0)2.1 (0.0 to 5.5)
SecondaryNumber of Participants With Death, Other Serious or Clinically Significant Adverse Events (AEs) or Related Discontinuations

National Cancer Institute (NCI)/ National Institute of Health (NIH) provides a grading (severity) scale for each AE term. Grade 3 refers to severe AE and Grade 4 refers to life-threatening or disabling AE. According to FDA 21CFR 314.80, a serious adverse event (SAE) is described as any adverse event that leads to death, is life threatening ( NIH criteria Grade 4), causes or prolongs hospitalization, results in a congenital anomaly, or any other important medical event not described above.

Time frame:
6 months - 1 year
Reported as:
Number · Participants
Number of Participants With Death, Other Serious or Clinically Significant Adverse Events (AEs) or Related Discontinuations
ParticipantsImatinib Mesylate + Hydroxyurea (HU)Hydroxyurea Alone
Deaths8491
Death due to disease progression7677
Serious Adverse Events (SAEs)6479
NCI/NIH Grade 3 (severe) or 4 (life threatening)5464
Suspected to be drug-related1212
Leading to dose adjustment or interruption616
Leading to permanent discontinuation913

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Imatinib Mesylate + Hydroxyurea (HU)—64/118 (54.2%)104/118 (88.1%)
Period With Hydroxyurea Alone—46/118 (39%)80/118 (67.8%)
Period After Switch to Combination—49/85 (57.6%)65/85 (76.5%)
Most frequent serious events
Showing 10 of 112
Most frequent serious events
EventImatinib Mesylate + Hydroxyurea (HU)Period With Hydroxyurea AlonePeriod After Switch to Combination
EPILEPSYNervous system disorders5/1189/1189/85
PNEUMONIAInfections and infestations9/1184/1185/85
HEMIPARESISNervous system disorders8/1185/1182/85
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders7/1186/1182/85
LEUKOPENIABlood and lymphatic system disorders1/1182/1185/85
CONVULSIONNervous system disorders3/1184/1184/85
INTRACRANIAL PRESSURE INCREASEDNervous system disorders3/1183/1184/85
PARTIAL SEIZURESNervous system disorders1/1182/1184/85
HEADACHENervous system disorders2/1185/1183/85
FALLInjury, poisoning and procedural complications3/1181/1183/85
Most frequent other events
Showing 10 of 41
Most frequent other events
EventImatinib Mesylate + Hydroxyurea (HU)Period With Hydroxyurea AlonePeriod After Switch to Combination
FATIGUEGeneral disorders34/11816/11818/85
OEDEMA PERIPHERALGeneral disorders29/11812/11814/85
NAUSEAGastrointestinal disorders28/11817/11810/85
HEADACHENervous system disorders26/11824/11816/85
THROMBOCYTOPENIABlood and lymphatic system disorders24/11815/11817/85
VOMITINGGastrointestinal disorders21/11813/1186/85
LEUKOPENIABlood and lymphatic system disorders16/11814/11814/85
ANAEMIABlood and lymphatic system disorders13/1188/11813/85
DIZZINESSNervous system disorders16/1183/1187/85
HYPOKALAEMIAMetabolism and nutrition disorders14/1182/1186/85

Baseline characteristics

Age Continuous
Age Continuous(years)Imatinib Mesylate + Hydroxyurea (HU)Hydroxyurea AloneTotal
Mean52.1 ± 11.350.2 ± 11.451.2 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)Imatinib Mesylate + Hydroxyurea (HU)Hydroxyurea AloneTotal
Female503888
Male7082152
08

Study locations

1 site
  • Novartis Investigative Site
    Duelmen, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004 and a primary completion of Aug 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 2 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 12, 2005
Start
Oct 2004
Primary completionActual
Aug 2008
Results first posted
Feb 2, 2011
Last update
Apr 26, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 26, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00154375
First posted
Sep 12, 2005
Start date
Oct 2004
Primary completion
Aug 2008
Results posted
Feb 2, 2011
Last update
Apr 26, 2011

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion